News & Insights

Dr. John Kenney

Dr. John Kenney

Recent posts by Dr. John Kenney

3 min read

COVID-19 Targets, Tools and Therapeutics (Part 1)

By Dr. John Kenney on 10/14/2020

Antibody Solutions is doing its part to respond to the COVID-19 pandemic, including original research, tool discovery, and participation in in-house and client-sponsored discovery programs. In this new blog series, we examine questions such as: What are the potential targets to treat COVID-19 and its sequelae, and what are the strategies and tools to discover drugs to treat the disease?

Topics: Insights Covid
6 min read

News Release: Study Identifies Potential COVID Vaccine & Therapy Research Pathways

By Dr. John Kenney on 06/17/2020

Conformational change of the spike protein furin cleavage domain may enhance virus infectivity

June 16, 2020 (Santa Clara, Calif.) — Research by two U.S.-based antibody discovery companies shows a rise and dominance of a mutant SARS-CoV-2 virus and identifies a new mechanism predicting a competitive advantage of the mutation. The mutation is predicted to induce a structural change in the spike protein of the virus that would enhance virus entry. The study, conducted by Antibody Solutions and Single Cell Technology (SCT), is available on (the study’s findings have not yet been peer-reviewed).

Topics: News Covid SARS-CoV-2 Molecuar Modeling
7 min read

Original Research: Joint effort finds advantages conferred by a D614G mutation in the SARS-CoV-2 spike protein

By Dr. John Kenney on 06/05/2020

It’s not often that small biotechnology companies pursue basic research into disease mechanisms. However, the serious impact of the SARS-CoV-2 outbreak on our families, friends, and community has prompted us to seek solutions for solving the COVID-19 pandemic. At Antibody Solutions (AS) and Single Cell Technology (SCT), we sought answers to the nature of the virus infection using our tools at hand.

Topics: Insights Covid SARS-CoV-2 Molecuar Modeling
5 min read

Antibody Solutions & the COVID-19 Crisis

By Dr. John Kenney on 04/19/2020

EDITOR'S NOTE: We're thankful to be holding true to the potential we outlined in this original April 19 blog post. As part of a collaboration with Single Cell Technology, we've discovered a potential new path for SARS-CoV-2 vaccine and therapy research. We've published our findings in a new paper, and you can get an overview here (as well as a link to the complete research document).


“It must be noted, however, that a single product is unlikely to meet the currently very substantial medical need, and not all product candidates will be successful in clinical studies. Therefore, many initiatives aimed at developing investigational antibodies are needed.”

— Dr. Janice Reichert, executive director, The Antibody Society

Where We Stand Now: The bottom line up-front

It’s probably safe to assume that—for all the wrong reasons—”coronavirus” will be Merriam-Webster’s word of the year for 2020. 

Topics: Insights Pink
1 min read

Antibody Solutions COVID-19 Update #2

By Dr. John Kenney on 04/02/2020

UPDATED 4/2/2020

On March 31, 2020, California Gov. Gavin Newsom extended the statewide shelter-in-place order through May 3, 2020. Additional restrictions designed to help protect citizens from the COVID-19 pandemic also were imposed.

Consistent with the March 19 order, this order considers life science companies such as Antibody Solutions to be “essential,” meaning we are exempt from many restrictions imposed on other businesses and can continue our operations. As specified in this order, we are preparing an updated document formalizing the social distancing protocol we had implemented in accordance with the first order.

Topics: News
1 min read

Antibody Solutions COVID-19 Update #1

By Dr. John Kenney on 03/17/2020

UPDATED 3/20/2020

On March 19, 2020, California Gov. Gavin Newsom announced statewide requirements in light of the COVID-19 pandemic. These required actions in this order align with the Santa Clara County shelter-in-place orders released earlier this week and have not imposed any additional restrictions on Antibody Solutions operations. We will continue to monitor this situation and provide updates, as necessary.  

On March 16, 2020, the Public Health Department of Santa Clara County, California, along with five other San Francisco Bay Area counties, issued a shelter-in-place order for all county residents in response to the COVID-19 pandemic. That includes us here at Antibody Solutions.

Topics: News
3 min read

Come Together, Right Now—For What Could Be

By Dr. John Kenney on 02/06/2020

Antibody Solutions’ Grand Opening Celebration | 01.30.20

From sparkling selfies and twirling mobiles of antibodies to insightful speeches, facility tours and tasty tacos, Antibody Solutions’ Grand Opening celebration last week had a little bit of everything. And we couldn’t be prouder!(*)

More than 125 treasured clients, partners and their families came together for what could be--and was—an evening of fun, festivity and friendship. We held the event to commemorate both our new 33,300-square-foot facility in Santa Clara, Calif., and the kickoff to our Silver Anniversary. The theme for our event was “25 Years of Revealing the Future,” and it was especially wonderful to welcome many guests who’ve been with us through the decades. 

Topics: News Purple
1 min read

Webinar: “Using Fluorescence-Activated Cell Sorting (FACS) for B-Cell Isolation”

By Dr. John Kenney on 11/13/2019

Isolating B cells can be a challenging exercise requiring careful planning, precise execution and the right technology. Over the years, the best method that we’ve found to help streamline and improve the efficiency and success of the process is Fluorescence-Activated Cell Sorting (FACS). 

Topics: Insights Pink
5 min read

Connecting the Dots: Discovery On Target 2019 Wrap-Up

By Dr. John Kenney on 10/18/2019

After a couple weeks of tackling the tsunami of emails, meetings and project updates that greeted me after my two-week “conference marathon” in Boston last month, here is a summary of Discovery on Target 2019. And, like the CAR-TCR Summit the week before, this year’s DOT (#17 in the series) offered a wide range of useful and interesting updates on the latest in antibody research.

Topics: Insights Green
3 min read

Already Strong & Gaining Momentum: CAR-TCR Summit 2019 Wrap-Up

By Dr. John Kenney on 10/17/2019

You know, it’s true -- there’s no place like home (especially Antibody Solutions’ new home in Santa Clara, California). At the same time, though, I probably would have stayed another week in Boston had there been a third conference that was as chock full of engaging presentations, intriguing research and useful data (plus some very stimulating hallway conversations) as the two back-to-back conferences I attended earlier this month: CAR-TCR Summit 2019 and Discovery on Target 2019.  

Topics: Insights Teal
5 min read

CAR-T Cell Therapy 101

By Dr. John Kenney on 08/29/2019

Chimeric antigen receptor (CAR-T) cell therapy

A growing number of CAR-T cell therapies are being developed and tested in clinical studies as an innovative approach to reprogram the patient’s immune system to attack its own abnormal cells. For treatment of certain cancers, as well as other diseases, this is a huge leap forward. 

Topics: Insights Pink
3 min read

Climbing for a Crucial Cause - Part 3

By Dr. John Kenney on 08/14/2019

Editor’s Note: This is the third and final post in a series on Dr. Oren Beske of ATUM and his climb up Mt. Kilimanjaro in support of the Fred Hutchinson Cancer Research Center. In an effort to avoid spoiling his inspiring last installment, we’ll just invite you to catch up on Oren’s first and second posts and then jump right in below.

Our thanks and congratulations to Oren and to all of you for supporting this terrific initiative! 

John Kenney

Co-Founder and CEO, Antibody Solutions

Topics: Insights Red
4 min read

Climbing for a Crucial Cause - Part 2

By Dr. John Kenney on 07/15/2019

Editor’s Note: Here’s the second installment in a blog post series we’re excited to present in conjunction with our friend and colleague Dr. Oren Beske of ATUM. If you missed Oren’s first post on his climb to help the Fred Hutchinson Cancer Research Center, you can read it here.

Thanks for continuing this journey with us. Onward and, more importantly, upward!

John Kenney

Co-Founder and CEO, Antibody Solutions

Topics: Insights Pink
3 min read

Climbing for a Crucial Cause

By Dr. John Kenney on 06/28/2019

Editor’s Note: We’re proud to present our first in a series of reflections from our friend and colleague, Dr. Oren Beske of ATUM. We think you’ll find the journey he’s on—one that’s both acutely personal yet wholly universal—to be inspiring and thought-provoking. At Antibody Solutions, we share the end goal of our oncology drug development partners and clients: To extend the quality and quantity of life for cancer patients, and, once and for all, to pitch cancer headfirst into the dustbin of medical history. We salute Oren and all those supporting the Fred Hutchinson Cancer Research Center (or, in shorthand, “Fred Hutch”). Climb well! 

Topics: Insights Purple
2 min read

Expanded Partnership Offers Antibody Solutions Clients Access to the Transgenic H2L2 Harbour Mice™ Platform

By Dr. John Kenney on 05/16/2019


Agreement Provides for Easy Access to the Transgenic H2L2 Harbour Mice™ Platform with Antibody Solutions’ Discovery and Development Services

Topics: News
2 min read

A New Way to Solve Problematic Rat IgG Purification

By Dr. John Kenney on 05/10/2019

When you think about the rat IgG production and purification process (especially IgG2a), what words often come to mind? If you’re like most researchers, it’s probably a combination of these: frustration, missed timelines, low purity, and poor recovery.

Topics: Insights
3 min read

PEGS  Boston 2019 Takeaways

By Dr. John Kenney on 04/24/2019

What do you get when you inject 2,600 participants into more than 400 sessions, 300-plus research posters and more than 150 exhibitors and then put ‘em all next to Boston Harbor for a week?

Topics: Insights Teal
2 min read

Keystone Joint Symposia Wrap-Up: A “Two-for-One” Win

By Dr. John Kenney on 03/07/2019

Earlier this month, I had the good fortune to attend the “Keystone Joint Symposia” event in Keystone, Colo. (and yes, it was much colder than at Antibody Solutions’ headquarters in Sunnyvale, Calif.!).The speakers during the sessions had two primary goals: (1) to present the most recent advances in the biology of T cell-dependent B cell responses; and (2) to explore how our understanding of B-T cell interactions influence antibody generation and inform vaccine development.

Topics: Insights Orange
1 min read

Success Rate of Different Antibody Platforms for Drug Discovery

By Dr. John Kenney on 03/07/2019

We are occasionally asked about the success rate of different antibody platforms for drug discovery. There are a variety of technologies available for therapeutic antibody discovery: conventional mice where the Abs are humanized, human Ab transgenic rodents, human Ab synthetic phage and yeast libraries, and others.

Topics: Insights Pink

Antibody Solutions News & Insights